Advertisement

ASO Author Reflections: Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells in Cholangiocarcinoma Patients

  • Yuki Kitano
  • Hideo BabaEmail author
ASO Author Reflections
  • 29 Downloads

Notes

Disclosures

Yuki Kitano and Hideo Baba have no conflict of interest to disclose.

References

  1. 1.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.CrossRefGoogle Scholar
  2. 2.
    Bordon Y. Tumour immunology: checkpoint parley. Nat Rev Immunol. 2015;15:5.CrossRefGoogle Scholar
  3. 3.
    Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.CrossRefGoogle Scholar
  4. 4.
    Gibbons Johnson RM, Dong H. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. Front Immunol. 2017;8:961.CrossRefGoogle Scholar
  5. 5.
    Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med. 2016;375:1767–78.CrossRefGoogle Scholar
  6. 6.
    Kitano Y, Yamashita Y, Nakao Y, et al. Clinical significance of PD-L1 expression in both cancer and stroma cells of cholangiocarcinoma patients. Ann Surg Oncol. Epub 12 Aug 2019.  https://doi.org/10.1245/s10434-019-07701-4.

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Gastroenterological Surgery, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan

Personalised recommendations